Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31361694 | 0.85 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1HTTCYP2D6KMT2A | |
| SCHEMBL29258460 | 0.84 | ALDH1A1 (0.38) | IRAK4ALDH1A1L3MBTL1HTTKMT2A | |
| SCHEMBL29258376 | 0.84 | ALDH1A1 (0.37) | IRAK4ALDH1A1L3MBTL1HTTKMT2A | |
| SCHEMBL29258806 | 0.84 | SIGMAR1 (0.39) | IRAK4ALDH1A1L3MBTL1KMT2ARXFP1 | |
| SCHEMBL29258453 | 0.84 | ALDH1A1 (0.34) | IRAK4ALDH1A1L3MBTL1KMT2ARXFP1 | |
| SCHEMBL29258363 | 0.83 | IRAK4 (0.38) | IRAK4ALDH1A1L3MBTL1HTTKMT2A | |
| SCHEMBL29258393 | 0.82 | L3MBTL1 (0.39) | IRAK4ALDH1A1L3MBTL1CYP2D6KMT2A | |
| SCHEMBL29258780 | 0.82 | ALDH1A1 (0.38) | IRAK4ALDH1A1L3MBTL1KMT2AACHE | |
| SCHEMBL29258406 | 0.82 | L3MBTL1 (0.40) | ALDH1A1L3MBTL1KMT2AACHE | |
| SCHEMBL29258384 | 0.81 | L3MBTL1 (0.39) | IRAK4ALDH1A1L3MBTL1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282768-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| EP-4522607-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2025-03-19 | — | — | EP | disclosed |
| WO-2025017116-A1 | PHARMACEUTICAL COMPOUNDS HAVING ACTIVITY AS WEE1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| CN-119317626-A | Pyrrolidone derivatives as inhibitors of NF- κb-induced kinase | 詹森药业有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-118108708-A | Aminopyrimidine derivative with antifungal activity and application thereof | 中国人民解放军海军军医大学 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023217851-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-κB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| EP-3099695-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-04-08 | — | — | EP | disclosed |
| US-20180354956-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-13 | — | — | US | disclosed |
| US-10087186-B2 | Compounds as LRRK2 kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-02 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| CN-105940004-A | Compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2016-09-14 | — | — | CN | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282768-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | IRAK4 33/4885ALDH1A1 4221/4885L3MBTL1 3866/4885 |
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | LRRK2, PARK7, PINK1 | IRAK4 1571/4885ALDH1A1 4033/4885L3MBTL1 304/4885 |
| US-10087186-B2 | Compounds as LRRK2 kinase inhibitors | LRRK2, PINK1, PARK7 | IRAK4 1318/4885ALDH1A1 4132/4885L3MBTL1 457/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | IRAK4 2181/4885ALDH1A1 3795/4885L3MBTL1 491/4885 |
| US-20180354956-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | IRAK4 2181/4885ALDH1A1 3795/4885L3MBTL1 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.